Advisory committee recommendations and a pending citizen petition may factor into FDA’s ongoing review of Amphastar Pharmaceuticals Inc.’s NDA for a nasal spray formulation of naloxone, the opioid overdose reversal agent, intended for use in non-health care settings.
Amphastar filed a new drug application (NDA) for intranasal naloxone in April, and the user fee goal date is Feb....




